Entrada Therapeutics Inc (NASDAQ:TRDA) Reports Q2 2025 Earnings Miss, Shares Drop in Pre-Market Trading

Entrada Therapeutics Inc (NASDAQ:TRDA) reported its second-quarter 2025 financial results, missing analyst estimates on both revenue and earnings per share (EPS). The company posted revenue of $1.95 million, significantly below the consensus estimate of $9.84 million, while its net loss per share came in at $1.04, worse than the expected loss of $0.86. The market reaction has been negative, with shares declining approximately 2% in pre-market trading, reflecting investor disappointment with the results.

Financial Performance vs. Estimates

• Revenue Miss: Reported revenue of $1.95 million was down sharply from $94.7 million in Q2 2024, primarily due to the substantial completion of collaboration research activities related to VX-670. Analysts had expected $9.84 million, making this a significant shortfall.
• Wider Loss Than Expected: The company’s net loss per share of $1.04 exceeded the estimated loss of $0.86, driven by higher R&D expenses ($37.9 million vs. $32.0 million in Q2 2024) and lower collaboration revenue.
• Cash Position: Entrada ended the quarter with $354 million in cash, cash equivalents, and marketable securities, providing a runway into Q2 2027.

Market Reaction

The stock’s pre-market decline suggests investors were anticipating better financial performance, particularly given the company’s progress in clinical trials. The miss on both top and bottom lines, combined with a year-over-year revenue drop, likely contributed to the negative sentiment. Over the past month, shares have declined by ~18.6%, indicating broader concerns about the company’s near-term revenue generation.

Key Business Updates

Despite the financial miss, Entrada made notable progress in its clinical pipeline:

• ELEVATE-44-201: First patient dosed in the Phase 1/2 study for Duchenne muscular dystrophy (DMD), with initial data expected in H1 2026.
• ELEVATE-45-201: Study initiation on track, with first patient dosing anticipated in Q3 2025.
• Regulatory Submissions: Plans to file for ENTR-601-50 in Q4 2025 and ENTR-601-51 in 2026.
• Leadership Additions: Strengthened its team with key hires in medical affairs and clinical development.

Outlook vs. Analyst Estimates

While the press release did not provide specific financial guidance, analysts currently expect:

• Q3 2025 Revenue: $9.59 million (vs. $1.95 million in Q2).
• Full-Year 2025 Revenue: $47.72 million (vs. $22.5 million in H1 2025).
• Q3 2025 EPS Estimate: -$0.92.
• Full-Year 2025 EPS Estimate: -$3.23.

Given the revenue decline and widening losses, investors will be closely watching whether upcoming clinical milestones can drive renewed confidence.

For more detailed earnings and estimates, visit Entrada Therapeutics’ earnings page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research before making any financial decisions.